Fenwick Represents Mendra in $82M Series A Funding

Fenwick represented Mendra, a biopharmaceutical company built to advance promising therapies for rare disease medicines, in its $82 million Series A funding. The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Wing VC.

Mendra will use the funds to acquire and develop initial rare disease assets for its portfolio. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partner Effie Toshav and included associates James Li, Tim Walker, and Kale Olmstead.